I don't think that's the case.  Its also in the annual Information Form for the year ended April 30th 2018 that was put out on July 27th 2018.  Here's the relevant section with my bolding:

The Third Eye Loan is guaranteed by our subsidiary and is secured by a first priority security interest in all of our present and future real and personal property, including all patents and other intellectual property and all securities of our subsidiary. The Third Eye Loan is subject to financial covenants requiring that we maintain a minimum market capitalization of $150 million, minimum monthly current ratio (defined as current assets divided by current liabilities) of 1:1 (excluding warrant liability, unearned revenues and debt from current liabilities), minimum cash balance of US$5 million, and other customary covenants. In addition, we are required to comply with certain affirmative covenants, including a requirement to obtain top-line results from the BETonMACE clinical trial by January 31, 2019, subject to an exception that is available in the event that additional patients are enrolled in the trial due to a sample size re-estimation analysis

And here's the link, the above section is on page 30.  Note that the exception based on needing additional patients is obviously out of play.

file:///C:/Users/Howard/Downloads/aif-resverlogix-corp-2018-04-30-2018-07-30.pdf